Previous Close | 0.0500 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 9.00 |
Expire Date | 2024-10-18 |
Day's Range | 0.0500 - 0.0500 |
Contract Range | N/A |
Volume | |
Open Interest | 10 |
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.